| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 05/26/2005 | US20050113299 Protein a compositions and methods of use |
| 05/26/2005 | US20050113291 Use of a substance which binds to and initiates signaling of the human SARP-1 receptor or a substance which stimulates release or potentiates the activity of endogenous SARP-1 for the manufacture of a medicament for the treatment and/or prevention of scleroderma, in particular of systemic sclerosis |
| 05/26/2005 | US20050112565 Proteases |
| 05/26/2005 | US20050112206 Mixture of drug, aminoacrylate polymer and acid |
| 05/26/2005 | US20050112146 Administering neurotoxin to infants; cerebral palsy therapy |
| 05/26/2005 | CA2547474A1 Genes differentially expressed by acutely isolated resident progenitor cells of the human white matter |
| 05/25/2005 | EP1532242A2 Methods for preparing purified prostaglandin e synthase |
| 05/25/2005 | EP1532152A1 Novel polymorph of n-methyl-n-(3- 3- 2-thienylcarbonyl]-pyrazol- 1,5-alpha]-pyrimidin-7-yl phenyl)acetamide and compositions and methods related thereto |
| 05/25/2005 | EP1532144A1 Novel quinuclidine derivatives and their use |
| 05/25/2005 | EP1531812A1 Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis |
| 05/25/2005 | EP1165081B1 Process for preparing tolperison-containing pharmaceutical preparations for oral administration |
| 05/25/2005 | EP0880362B1 Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene b 4 receptor antagonist |
| 05/25/2005 | DE10359336A1 Use of potassium channel openers in synergistic combination with sodium channel inhibiting/influencing active compounds for treating pains accompanied by increase in muscle tone |
| 05/25/2005 | DE10359335A1 Kombinationen aus Kaliumkanalöffnern und Natriumkanalinhibitoren oder Natriumkanal beeinflussenden Wirkstoffen zur Behandlung von Schmerzzuständen Combinations of potassium channel openers and sodium channel inhibitors and sodium channel influencing agents for the treatment of pain |
| 05/25/2005 | CN1620467A Secreted protein |
| 05/25/2005 | CN1620461A 2-amino-propanol derivatives |
| 05/25/2005 | CN1620301A Pharmaceutically acceptable phosphate-glycerol carrying bodies |
| 05/25/2005 | CN1203061C Substituted isoquinolines, its preparing process, medical composition and its use for preparing medicine |
| 05/25/2005 | CN1203060C Pyridine derivatives, its composition and use |
| 05/24/2005 | US6897319 Therapeutic drugs for treating central nervous system disorders |
| 05/24/2005 | US6897219 Central nervous system diosrders; analgesics; antiinflammatory agents |
| 05/19/2005 | US20050108785 Using nuclear transplantation as tool in generating transgenic cells for treatment and prevention of liver, nervous system, cardiovascular and bone disorders; regenerative medicine |
| 05/19/2005 | US20050107432 such as 1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-ylidene]methylpiperidine, used for treating nervous system, neurodegenerative and/or psychological disorders |
| 05/19/2005 | US20050107428 Antiinflammatory agents; autoimmune diseases; rheumatic diseases; anticholesterol agents; cardiovascular disorders |
| 05/19/2005 | US20050107416 17-hydroxy 4-aza androstan -3-ones as androgen receptor modulators |
| 05/19/2005 | US20050107413 pyrimidine derivatives such as 4-Chloro-5,6-diphenyl-2-(trifluoromethyl)pyrimidine, used for the treatment of inflammation and immunological diseases |
| 05/19/2005 | US20050107384 to inhibit proliferative conditions, such as cancer and psoriasis; detecting or identifying a HDAC in a biological sample comprising detecting or measuring the formation of a complex between a labelled compound as defined in claim (I) and a HDAC |
| 05/19/2005 | US20050107345 Aminoalkylphosphonates and related compounds as edg receptor agonists |
| 05/19/2005 | US20050106724 Self renewing dental follicle tissues for use in generating periodontal ligament like membrane structures; tissue repair and regenerative medicine |
| 05/19/2005 | US20050106695 Cell-permeable peptide inhibitors of the jnk signal transduction pathway |
| 05/19/2005 | US20050106679 Leptin proteins |
| 05/19/2005 | US20050106266 docosahexaenoic acid and a calcium compound (carbonate, hydroxide,sulfate) |
| 05/19/2005 | US20050106234 Calcium formate for use as a dietary supplement |
| 05/19/2005 | US20050106154 GASP1: a follistatin domain containing protein |
| 05/19/2005 | US20050106140 Antagonistic anti-hfas ligand human antibodies and fragments thereof |
| 05/19/2005 | US20050106127 Graft to humans; culture product; removing cells; preservation |
| 05/18/2005 | EP1530632A2 Growth factor which acts through erb b-4 rtk |
| 05/18/2005 | EP1530586A2 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
| 05/18/2005 | EP1530568A1 INDOLE OR BENZIMIDAZOLE DERIVATIVES FOR MODULATING I&kB KINASE |
| 05/18/2005 | EP1530565A1 Substituted thiophene carboxamide compounds for the treatment of inflammation |
| 05/18/2005 | EP1530483A2 T cell receptor cdr3 sequences and methods for detection |
| 05/18/2005 | EP1301502B1 Compounds and their use as glycine transport inhibitors |
| 05/18/2005 | EP1265860B1 Amidino compound and salts thereof useful as nitric oxide synthase inhibitors |
| 05/18/2005 | EP1263724B1 Novel compounds |
| 05/18/2005 | CN1617888A Bispecific antibody DNA constructs for intramuscular administration |
| 05/18/2005 | CN1617887A Corticotropin releasing factor receptor 2 agonists |
| 05/18/2005 | CN1617886A Corticotropin releasing factor receptor 2 agonists |
| 05/18/2005 | CN1617885A Corticotropin releasing factor receptor 2 agonists |
| 05/18/2005 | CN1617736A Vaccine and method for treatment of motor neurone diseases |
| 05/18/2005 | CN1617720A Use of pramipexole to treat amyotrophic lateral sclerosis |
| 05/18/2005 | CN1617716A Heterocycle derivatives and methods of use |
| 05/18/2005 | CN1617715A Treating muscle wasting with selective androgen receptor modulators |
| 05/18/2005 | CN1617711A Liposomal delivery of vitamin E based compounds |
| 05/18/2005 | CN1616084A Botulinum toxin pharmaceutical compositions |
| 05/18/2005 | CN1202104C 2-phenylpyran-4-one derivatives |
| 05/17/2005 | US6894155 Immumodulatory protein for use in the treatment of nervous system, skin and immunological disorders |
| 05/17/2005 | US6894067 5-heteroatom-substituted pyrazoles |
| 05/17/2005 | US6894054 Central nervous system disorders; muscular disorders |
| 05/17/2005 | US6894042 Azabicyclic compounds for the treatment of disease |
| 05/17/2005 | US6894041 Oxazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes |
| 05/17/2005 | US6894038 Administering an estriol 3,17-dipropionate or an estriol 3,17-dihexanoate, for treating multiple sclerosis |
| 05/17/2005 | US6893858 Human kcnq5 potassium channel, methods and compositions thereof |
| 05/17/2005 | US6893641 Ganoderma lucidum spores for treatment of autoimmune diseases |
| 05/12/2005 | WO2005042727A2 Methods of organ regeneration |
| 05/12/2005 | WO2003070903A3 RNA INTERFERENCE MEDIATED INHIBITION OF GRB2-ASSOCIATED BINDING PROTEIN 2 (GAB2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 05/12/2005 | US20050101649 nicotinic alpha 7 receptor and 5-HT3 or 5-HT6 receptor; control of cholinergic and dopaminergic neurotransmission; disorders of the central nervous system and serotonergic hyperactivity; psychiatric and neurodegenerativce disorders; antiemetics during chemotherapy |
| 05/12/2005 | US20050101612 Use of indole-3-acetic acids in the treatment of asthma, copd and other diseases |
| 05/12/2005 | US20050101567 Using a sulfonamide containing compound |
| 05/12/2005 | US20050101563 Using cyclooxygenase inhbitor and fatty acid; analgesics; antiinflammatory agents; antiarthritic agents; vision defects; urogenital disorders; gastrointestinal disorders |
| 05/12/2005 | US20050101529 Protein modification and maintenance molecules |
| 05/12/2005 | US20050100536 Platelet rich plasma, no exogenous activator; sodium bicarbonate buffer, citrate dextrose anticoagulant |
| 05/12/2005 | CA2543745A1 Methods of organ regeneration |
| 05/11/2005 | EP1529105A1 Methods to reprogram splice site selection in pre-messenger rnas |
| 05/11/2005 | EP1397363B1 5-ethyl-imidazotriazinones |
| 05/11/2005 | EP1128829B1 Riluzole and alpha-tocopherol combination |
| 05/11/2005 | EP0971898B1 Substituted isoquinolines as ultra short acting neuromuscular blockers |
| 05/11/2005 | CN1615149A Drug mobilizing pluripotent stem cells from tissue into peripheral blood |
| 05/11/2005 | CN1615148A Methods and compositions for derepression of IAP-inhibited caspase |
| 05/11/2005 | CN1200715C Adetphos sodium chloride injection and its preparation method |
| 05/11/2005 | CN1200713C New (aminopropyl) methylphosphinic acids |
| 05/11/2005 | CN1200704C Appliance of probucol monoesters for treatment of cardiovascular and inflammatory disease |
| 05/11/2005 | CN1200691C Oral solution containing galanthamine and sweetening agent |
| 05/10/2005 | US6890945 Administering a imidazo(4,5,1-ij)quinoline compound |
| 05/10/2005 | US6890927 Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
| 05/10/2005 | US6890915 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
| 05/10/2005 | US6890751 NRG-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods |
| 05/06/2005 | WO2005039602A1 Pharmacologically functional water and use thereof |
| 05/06/2005 | WO2005039577A1 Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pain |
| 05/06/2005 | WO2005039576A1 Combinations of potassium channel openers and sodium channel inhibitors or active substances influencing sodium channels in order to treat painful conditions |
| 05/06/2005 | WO2005039541A1 Coenzyme q10 enclosing capsule |
| 05/06/2005 | WO2003010286A3 Nucleic acids, polypeptides, and methods for modulating apoptosis |
| 05/06/2005 | CA2542434A1 Combination of flupirtine and tolperisone or eperisone for the treatment of painful conditions |
| 05/05/2005 | US20050096468 Inhibitors of histone deacetylase |
| 05/05/2005 | US20050096392 Use of creatine pyruvate for increasing stamina during highly intensive intermittent physical exertion |
| 05/05/2005 | US20050096334 Use of substance P antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of NK-1 receptor antagonists for the treatment of chronic fatigue syndrome |
| 05/05/2005 | US20050096330 N-(indolecarbonyl) piperazine derivatives |
| 05/05/2005 | US20050096312 Antiserotonine agents; antidepressants; eating disorders; anxiolytic agents; sleep disorders; gastrointestinal disorders; cardiovascular disorders; muscular disorders; endocrine system diseases; muscular disorders; psychological disorders |
| 05/05/2005 | US20050095248 Use of inhibitor of cathepsin S based upon peptide sequence which comprises at least about 2-20 consecutive residues from preferred invariant chain cleavage site of cathepsin S, spanning from residue 68 to residue 90 of specified sequence |
| 05/04/2005 | EP1528058A1 Polymorphic crystalline forms of celecoxib |
| 05/04/2005 | EP1527075A1 Diazabicyclononane and -decane derivatives and their use as opioid receptor ligands |